11th LIPIDCLUB 2016 The MIGHTY MEDIC Gobal Scientific Society
[slideshow_deploy id=’1008′]
Therapeutic algorithm for Patients with severe Hypercholesterolemia or isolated Lipoprotein(a)-Hyperlipoproteinemia with progressive cardiovascular disease: PCSK9-Inhibitors, Lipoprotein Apheresis or both? Nephrologisches Zentrum GöttingenGbR Priv. Doz. Dr.med. V. Schettler
Giovedì 12 Maggio 2016 AUDITORIUM MINISTERO DELLA SALUTE Lungotevere Ripa, 1 ROMA La diffusione della malattia in Italia ed nel Lazio La prevalenza storica, rispettivamente della Ipercolesterolemia Familiare (IF) Omozigote ed Eterozigote è di 1: 1000000 e di 1:500. In Italia circa 2200 ragazzi sotto i 14 anni soffrono …
WAA/SFH Joint Congress, Paris, 27–29 April 2016
Authors: John J.P. Kastelein, Gisle Langslet, Paul Hopkins, Joep Defesche, Werner Seiz, Marie Baccara-Dinet, Sara Hamon, Poulabi Banerjee, Claudia Stefanutti, Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA, Sanofi, Montpellier, France Background: Next Generation Sequencing was performed to examine treatment response with alirocumab in patients carrying one or more causative mutation(s) in five familial …
Familial hypercholesterolemia (FH) is characterized by high levels of low-density lipoprotein cholesterol (LDL-C) and increased risk of developing premature coronary heart disease. The prevalence of heterozygous and homozygous FH has been estimated to be 1:200 to 1:500 and 1:160,000 to 1:1,000,000, respectively. In plasma, LDL-C levels are regulated via apolipoprotein …
“PREVENTION IN PEDIATRICS – BASIS FOR HEALTHY LIFE AND LONGEVITY” 15 – 17 April 2016. Hotel Holiday Inn, Belgrade
Serbia Assoc of Peds: Final Program [slideshow_deploy id=’1019′]
http://www.ncbi.nlm.nih.gov/pubmed/19927363